Integrum ABOSTO:INTEG B +0.24%53 Piotroski F-Score is 2 as of Jul. 03, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates OSTO:INTEG B with a GF Score™ of 53/100 and a GF Value™ of kr17.76 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Integrum AB ranks worse than 89.95% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Integrum AB has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Integrum AB's Piotroski F-Score or its related term are showing as below:
OSTO:INTEG B'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 6
Current: 2
During the past 12 years, the highest Piotroski F-Score of Integrum AB was 6. The lowest was 1. And the median was 4.
Integrum AB (OSTO:INTEG B) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Integrum AB Piotroski F-Score Related Terms
Integrum AB Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Integrum AB's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:INTEG B vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Integrum AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Integrum AB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Integrum AB's current Net Income (TTM) was -46.34.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Integrum AB's return on assets of this year was -0.22819027. Integrum AB's return on assets of last year was -0.18713567.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Integrum AB's gearing of this year was 0.00709163. Integrum AB's gearing of last year was 0.01689917.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Integrum AB's current ratio of this year was 2.77132733. Integrum AB's current ratio of last year was 4.53884216.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Integrum AB's number of shares in issue this year was 26.668. Integrum AB's number of shares in issue last year was 21.334.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Integrum AB's gross margin of this year was 0.69185315. Integrum AB's gross margin of last year was 0.82746432.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Integrum AB's asset turnover of this year was 0.45003275. Integrum AB's asset turnover of last year was 0.55259343.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Integrum AB has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Integrum AB (OSTO:INTEG B) has a Piotroski F-Score of 2 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Integrum AB and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Integrum AB's Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, Integrum AB ranks #725 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 90%.
Is Integrum AB's Piotroski F-Score too high?
Integrum AB's current Piotroski F-Score of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Integrum AB's value of 2 is 60% below this industry median. Based on the distribution chart, Integrum AB ranks #725 out of 806 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integrum AB has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #725 out of 806 companies for Piotroski F-Score. This places Integrum AB in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Integrum AB's value of 2 is 60% below this benchmark. Historically, Integrum AB's own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Integrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrum AB's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Integrum AB and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current Piotroski F-Score is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (OSTO:INTEG B) is currently considered Possible Value Trap. The stock's GF Value™ is kr17.76, compared to a current price of kr8.22 — trading 53.7% below its estimated fair value. The current Piotroski F-Score is 2, which is 50% below median its 10-year median of 4.00 and 60% below the Medical Devices & Instruments industry median of 5.00. Integrum AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Integrum AB (OSTO:INTEG B), the current Piotroski F-Score is 2 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (OSTO:INTEG B) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of kr8.22 is trading 53.7% below its estimated GF Value™ of kr17.76.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for OSTO:INTEG B:
Piotroski F-Score: 2 (50% below median its 10-year median of 4.00)
GF Value™: kr17.76 vs. price of kr8.22 (53.7% below fair value)
Industry Position: 60% below the Medical Devices & Instruments median (#725 of 806)
No single metric tells the full story. See the OSTO:INTEG B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
53GF Score
Get the complete analysis for OSTO:INTEG B
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:INTEG B has been successfully added to your 
